The Clinical Dilemma: Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) require fundamentally different treatment approaches. SCLC is typically managed with chemotherapy and radiation, while NSCLC can be surgically resected. Misclassification at diagnosis leads to inappropriate and potentially harmful treatment.
Diagnostic Challenges in Peripheral Stage III Tumors: Peripheral lung tumors at stage III can be difficult to biopsy adequately, and cytology or small biopsy samples sometimes fail to definitively distinguish SCLC from NSCLC. An imaging-based preoperative model would complement pathological workup.
Radiomics as a Solution: Radiomics extracts large numbers of quantitative features from CT images - including shape, texture, and intensity metrics - that may encode biological differences invisible to the human eye. Combined with clinical parameters, these features could enable accurate non-invasive classification.
Study Objective: This study aimed to develop and validate a predictive model combining CT radiomic features and clinical parameters to preoperatively differentiate resectable stage III peripheral SCLC from NSCLC, supporting better surgical planning and treatment selection.
Patient Cohorts: The study enrolled patients with pathologically confirmed peripheral stage III SCLC or NSCLC from multiple institutions. Patients were divided into a training set, an internal test set, and an external validation cohort to rigorously evaluate model generalizability.
CT Image Segmentation: Tumor regions of interest were manually delineated by radiologists on preoperative CT scans. Segmentation masks defined the volume within which radiomic features were computed, ensuring consistent feature extraction across patients.
Feature Extraction and Selection: Hundreds of radiomic features were extracted using standardized software (PyRadiomics), including first-order statistics, shape metrics, GLCM texture features, and wavelet-transformed features. LASSO regression and univariate analysis reduced the feature set to those most predictive of cancer type.
Model Development: A radiomic signature was combined with independent clinical predictors identified through logistic regression. The final combined model was constructed and its performance evaluated using AUC, sensitivity, specificity, and calibration.
Age and Smoking History: SCLC patients in this cohort tended to be older with heavier smoking histories compared to NSCLC patients. Smoking pack-years emerged as an independent clinical predictor in the combined model, reflecting the strong smoking-SCLC association.
CEA and NSE Serum Markers: Neuron-specific enolase (NSE) is a well-established SCLC marker, and elevated NSE was a strong predictor of SCLC. Carcinoembryonic antigen (CEA) levels, more commonly elevated in adenocarcinoma, contributed in the opposite direction.
Tumor Location and Morphology: SCLC tumors were more likely to appear centrally-adjacent even within the peripheral category, with less lobulation and fewer spiculations than NSCLC. These imaging patterns were captured in part by radiomic shape features.
Lymphadenopathy: SCLC is known for early mediastinal lymph node involvement. The presence and extent of hilar and mediastinal lymphadenopathy on CT was incorporated as a clinical variable and contributed significant predictive weight to the combined model.
Training Set AUC: The combined radiomic-clinical model achieved an AUC of 0.956 in the training cohort, indicating near-excellent discrimination between SCLC and NSCLC based on CT and clinical features alone.
Internal Test Set Performance: On the internal test set, the model maintained an AUC of 0.905, confirming that performance was not inflated by overfitting to the training data and that the model captures genuinely generalizable patterns.
External Validation AUC: In the independent external validation cohort, the model achieved an AUC of 0.843, representing a moderate drop but still strong discriminative performance in a completely independent sample with potentially different imaging protocols.
Comparison with Individual Components: The combined model consistently outperformed radiomic-only and clinical-only models at all evaluation points, validating the complementary information provided by integrating imaging features with clinical parameters.
Nomogram or Scoring Tool: The finalized model was presented as a practical scoring tool that clinicians can use by inputting radiomic scores and clinical values. The output provides a probability estimate of SCLC versus NSCLC, giving treating physicians a quantitative pre-biopsy or pre-surgery estimate.
Decision Support for Borderline Cases: In cases where biopsy material is non-diagnostic or where cytology provides equivocal results, the model score could guide further workup (e.g., rebiopsy, EBUS, or bronchoscopy) or prompt consideration of empirical chemotherapy for presumed SCLC.
Surgical Planning: For surgeons evaluating resectability in stage III peripheral tumors, a high SCLC probability score would counsel against upfront surgery and redirect the patient toward chemoradiation or prophylactic cranial irradiation evaluation.
Prospective Implementation: Decision curve analysis confirmed net clinical benefit from using the model over default treat-all or treat-none strategies across a range of threshold probabilities, supporting its practical utility in real-world clinical workflows.
Retrospective Multi-Center Design: Despite external validation, the study is retrospective and CT protocols may have varied across centers. Radiomic features are sensitive to acquisition parameters, and prospective standardization would improve reproducibility.
Manual Segmentation Variability: Tumor segmentation was performed manually by radiologists, introducing potential inter-observer variability. Semi-automated or AI-driven segmentation workflows could improve consistency in future applications.
Limited SCLC Sample Size: Because SCLC accounts for only about 15% of lung cancers, the number of SCLC cases in any single dataset is relatively small. Larger multi-institutional collaborations would provide more statistical power to refine the model.
Integration with Molecular Data: Future models that incorporate molecular features such as gene expression, PD-L1 status, or ctDNA could further improve classification and potentially enable simultaneous histotype prediction and biomarker profiling from a single CT scan.